Table 3.
Bivariate and multivariate analysis by AFT model for time to interruption (of NFX treatment)
| Covariate | Bivariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|---|
| Coefficient (βi) | TR exp(βi) | 95% CI | P value | Coefficient (βi) | TR exp(βi) | 95% CI | P value | |
| Severity | ||||||||
| Severe | Ref | Ref | – | – | Ref | Ref | – | – |
| Mild/moderate | 1.82 | 6.20 | (2.84–13.6) | < 0.001 | 1.88 | 6.52 | (3.24–13.1) | < 0.001 |
| Doses mg/kg/day | ||||||||
| > 8 | Ref | Ref | – | – | Ref | Ref | – | – |
| ≤ 8 | 1.01 | 2.77 | (0.89–8.59) | 0.077 | 0.57 | 1.78 | (0.90–3.49) | 0.095 |
| Age (years) | ||||||||
| ≥ 48 | Ref | Ref | – | – | Ref | Ref | – | – |
| < 48 | −0.08 | 0.92 | (0.34–2.49) | 0.874 | 0.45 | 1.57 | (0.90–2.74) | 0.109 |
| ADRs | ||||||||
| > 3 | Ref | Ref | – | – | Ref | Ref | – | – |
| ≤ 3 | 0.92 | 2.51 | (1.39–4.51) | 0.002 | 0.58 | 1.78 | (1.04–3.03) | 0.033 |
| Sex | ||||||||
| Male | Ref | Ref | – | – | – | – | – | – |
| Female | 0.55 | 1.72 | (0.74–4.01) | 0.203 | – | – | – | – |
| History of previous pathologies | ||||||||
| Yes | Ref | Ref | – | – | – | – | – | – |
| No | 0.67 | 1.95 | (0.82–4.64) | 0.129 | – | – | – | – |
| Alteration of leukocytes | ||||||||
| Yes | Ref | Ref | – | – | – | – | – | – |
| No | 0.01 | 1.01 | (0.23–4.40) | 0.921 | – | – | – | – |
| Alteration of lymphocyte | ||||||||
| Yes | Ref | Ref | – | – | – | – | – | – |
| No | 0.29 | 1.33 | (0.70–2.56) | 0.378 | – | – | – | – |
| Alteration of neutrophils | ||||||||
| Yes | Ref | Ref | – | – | – | – | – | – |
| No | 0.46 | 1.59 | (0.51–5.01) | 0.426 | – | – | – | – |
| Alteration of eosinophil | ||||||||
| Yes | Ref | Ref | – | – | – | – | – | – |
| No | 0.08 | 1.08 | (0.57–2.07) | 0.795 | – | – | – | – |
ADRs = adverse drug reactions; AFT = accelerated failure time model; CI = confidence interval; NFX = nifurtimox; Ref = reference variable; TR = time ratio.
Bold values are statistically significant results P < 0.005.